About this trial
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography
Provided written informed consent
Disqualifiers
Severe hepatic or renal insufficiency
Malignancy under active treatment
Severe infection
Active autoimmune disease
Trial design
Treatments tested in this trial
- Not listed